NCT00424021View on ClinicalTrials.gov

Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension

PHASE2CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Pulmonary Hypertension

Interventions

DRUG

ambrisentan

1, 2.5, 5, and 10 mg ambrisentan given orally once daily

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY